Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 3, pp 387–392 | Cite as

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates

  • Holly J. Meany
  • Elizabeth Fox
  • Cynthia McCully
  • Chris Tucker
  • Frank M. Balis
Original Article

Abstract

Purpose

Erlotinib hydrochloride is a small molecule inhibitor of epidermal growth factor receptor (EGFR). EGFR is over-expressed in primary brain tumors and solid tumors that metastasize to the central nervous system. We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics of erlotinib and its active metabolite OSI-420 after an intravenous (IV) dose in a non-human primate model.

Methods

Erlotinib was administered as a 1 h IV infusion to four adult rhesus monkeys. Serial blood and CSF samples were drawn over 48 h and erlotinib and OSI-420 were quantified with an HPLC/tandem mass spectroscopic assay. Pharmacokinetic parameters were estimated using non-compartmental and compartmental methods. CSF penetration was calculated from the AUCCSF:AUCplasma.

Results

Erlotinib disappearance from plasma after a short IV infusion was biexponential with a mean terminal half-life of 5.2 h and a mean clearance of 128 ml/min per m2. OSI-420 exposure (AUC) in plasma was 30% (range 12–59%) of erlotinib, and OSI-420 clearance was more than 5-fold higher than erlotinib. Erlotinib and OSI-420 were detectable in CSF. The CSF penetration (AUCCSF:AUCplasma) of erlotinib and OSI-420 was <5% relative to total plasma concentration, but CSF drug exposure was ∼30% of plasma free drug exposure, which was calculated from published plasma protein binding values. The IV administration of erlotinib was well tolerated.

Conclusions

Erlotinib and its active metabolite OSI-420 are measurable in CSF after an IV dose. The drug exposure (AUC) in the CSF is limited relative to total plasma concentrations but is substantial relative the free drug exposure in plasma.

Keywords

Erlotinib Pharmacokinetics Cerebrospinal fluid Non-human primate 

References

  1. 1.
    Broniscer A, Panetta JC, O’Shaughnessy M, Fraga C, Bai F, Krasin MJ, Gajjar A, Stewart CF (2007) Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 13:1511–1515PubMedCrossRefGoogle Scholar
  2. 2.
    Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Klencke B, Mischel P (2005) Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. Am Soc Clin Oncol Ann Meeting Proc 23:Abst #1507Google Scholar
  3. 3.
    Fox E, Bungay PM, Bacher J, McCully CL, Dedrick RL, Balis FM (2002) Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 301:1003–1011PubMedCrossRefGoogle Scholar
  4. 4.
    Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46:282–290PubMedCrossRefGoogle Scholar
  5. 5.
    Grunwald V, Hidalgo M (2003) Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30:23–31PubMedCrossRefGoogle Scholar
  6. 6.
    Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47:87–98PubMedGoogle Scholar
  7. 7.
    Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887PubMedCrossRefGoogle Scholar
  8. 8.
    Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74–89PubMedCrossRefGoogle Scholar
  9. 9.
    Hidalgo M, Bloedow D (2003) Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 30:25–33PubMedGoogle Scholar
  10. 10.
    Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H (2005) Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 43:661–669PubMedCrossRefGoogle Scholar
  11. 11.
    Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420–426PubMedGoogle Scholar
  12. 12.
    Loscher W (1979) A comparative study of the protein binding of anticonvulsant drugs in serum of dog and man. J Pharmacol Exp Ther 208:429–435PubMedGoogle Scholar
  13. 13.
    Lutsar I, McCracken GH Jr, Friedland IR (1998) Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27:1117–1127, quiz 1128–1119PubMedCrossRefGoogle Scholar
  14. 14.
    McCully CL, Balis FM, Bacher J, Phillips J, Poplack DG (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520–525PubMedGoogle Scholar
  15. 15.
    Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848PubMedGoogle Scholar
  16. 16.
    Nau R, Sorgel F, Prange HW (1998) Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 35:223–246PubMedCrossRefGoogle Scholar
  17. 17.
    Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16PubMedCrossRefGoogle Scholar
  18. 18.
    Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncology 8:67–78Google Scholar
  19. 19.
    Rao RD, James CD (2004) Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 31:595–604PubMedCrossRefGoogle Scholar
  20. 20.
    Razier J, Abrey L, Wen P, Cloushesy T (2004) A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Am Soc Clin Oncol Ann Meeting Proc 22:Abst #1502Google Scholar
  21. 21.
    Sutter AP, Hopfner M, Huether A, Maaser K, Scherubl H (2006) Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 118:1814–1822PubMedCrossRefGoogle Scholar
  22. 22.
    Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193PubMedCrossRefGoogle Scholar
  23. 23.
    Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C (2004) Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: interim results. Am Soc Clin Oncol Ann Meeting Proc 22:Abst #1558Google Scholar
  24. 24.
    Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241–250PubMedCrossRefGoogle Scholar
  25. 25.
    Zhao M, He P, Rudek MA, Hidalgo M, Baker SD (2003) Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793:413–420PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Holly J. Meany
    • 2
  • Elizabeth Fox
    • 1
  • Cynthia McCully
    • 1
  • Chris Tucker
    • 3
  • Frank M. Balis
    • 1
  1. 1.Pediatric Oncology BranchNational Cancer InstituteBethesdaUSA
  2. 2.Children’s National Medical CenterWashingtonUSA
  3. 3.OSI PharmaceuticalsBoulderUSA

Personalised recommendations